Investigational drug · Phase 3
2 NRTIs
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
127
Any phase or sponsor naming "2 NRTIs"
First trial start
2016
Oct 28, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "2 NRTIs", any sponsor or status.
Conditions studied
As listed on its trial records.
- Human Immunodeficiency Virus (HIV) Infection
- Infection, Human Immunodeficiency Virus
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "2 NRTIs" as an intervention, largest first.
ViriomIndustry
NCT03706950 · 2,000 participants (planned) · Start Mar 15, 2018 · Primary completion Dec 31, 2021
Drug: Elpida® + 2 NRTIs · For: HIV-1-infection
Sites: Astrakhan, Russia; Barnaul, Russia; Chelyabinsk, Russia · 11 sites in all
- Comparative Study of Three NNRTI-Sparing HAART RegimensPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00811954 · 1,814 participants · Start May 2009 · Primary completion Jun 2013
Drug: Emtricitabine/tenofovir disoproxil fumarate; Raltegravir and 3 more · For: HIV Infection
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 57 sites in all
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionPivotal-lookingStatus unknown
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
NCT04064632 · 1,609 participants · Start Feb 1, 2017 · Primary completion Jun 13, 2019
Drug: Rilpivirine + darunavir/cobicistat · For: HIV Infection
Sites: Bergamo, Italy
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02140255 · 1,120 participants (planned) · Start Jan 23, 2015 · Primary completion Jan 31, 2028
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP) and 5 more · For: HIV Infection
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 47 sites in all
- Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)Pivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT02346487 · 1,003 participants · Start Sep 2015 · Primary completion May 14, 2019
Drug: LPV/RTV pellets and AZT/3TC or ABC/3TC · For: HIV
Sites: Eldoret, Kenya; Kisumu, Kenya; Nairobi, Kenya · 11 sites in all
- Dolutegravir and Darunavir Evaluation in Adults Failing TherapyPivotal-lookingStatus unknown
Kirby InstituteGovernment (non-federal)
NCT03017872 · 831 participants · Start Nov 23, 2017 · Primary completion Nov 11, 2022
Drug: NRTIs; Dolutegravir and 2 more · For: HIV Infections
Sites: Isidro Casanova, Argentina; Buenos Aires, Argentina; Rosario, Argentina · 28 sites in all
- A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected PatientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00002378 · 825 participants
Drug: Ritonavir; Nelfinavir mesylate and 5 more · For: HIV Infections
Sites: Anniston, Alabama; Phoenix, Arizona; Tucson, Arizona · 102 sites in all
- Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00050895 · 775 participants
Drug: Lopinavir/ritonavir; Efavirenz and 4 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 60 sites in all
- NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV TransmissionPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00089505 · 745 participants · Start Nov 2006 · Primary completion Aug 2010
Drug: Emtricitabine; Emtricitabine/Tenofovir disoproxil fumarate and 3 more · For: HIV Infections
Sites: Bontleng, Botswana; Bontleng Gaborone, Botswana; Eldoret, Kenya · 11 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02397096 · 673 participants · Start Jun 9, 2015 · Primary completion Feb 22, 2018
Drug: Doravirine, Tenofovir, Lamivudine; Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor and 3 more · For: HIV-1 Infection
Newest research
PubMed records naming it or its code names, newest first.
- HIV viral suppression in children and adolescents who transitioned from ritonavir-boosted lopinavir- to dolutegravir-based antiretroviral therapy in Lesotho.
Blankenberger J, Steffy TLF, Lee T, et al. · HIV Med 2026
- Effects of different highly active antiretroviral therapy regimens on immune, biochemical indicators, and viral suppression in HIV/AIDS patients in Southwest China.
Nie Z, Zheng Y, Ao S, et al. · Sci Rep 2026
- Association of antiretroviral therapy regimens with serum cortisol abnormalities in people living with HIV/AIDS: a retrospective study.
Yajuan H, Xingxing C, Huirong J, et al. · Front Endocrinol (Lausanne) 2026
- Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis.
Curteis T, Eddowes LA, Karlsson A, et al. · J Comp Eff Res 2026
- Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
Hsue PY, Behrens GMN, Xu ZJ, et al. · J Acquir Immune Defic Syndr 2026
- Pre-treatment and acquired HIV drug resistance in Hunan: a cross-sectional analysis of a growing challenge.
Long S, Yao R, Tang Y, et al. · BMC Infect Dis 2025
Also in development for Human Immunodeficiency Virus (HIV) Infection
- MK-1439APhase 21 trial
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.